Accelerated Approval Could Be Even Faster With Intermediate Clinical Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy and Commerce Committee asked to encourage FDA to use the often forgotten option of intermediate clinical endpoints.